VIVE (Viveve Medical) NASDAQ pre-market up 19,900% on 13 Mar 2026: top gainer insight

VIVE stock leads pre-market movers on the NASDAQ on 13 Mar 2026 after a sharp price move to $0.0002, a 19,900.00% one-day change on minimal volume. The move comes on extremely low liquidity with 581 shares traded versus an average 1,883 shares. We outline why the spike matters, the company’s fundamentals, and what traders should watch before the upcoming earnings announcement on 2026-03-20. This preview uses Meyka AI real-time tools and market context for VIVE stock.

VIVE stock pre-market move and trading snapshot

VIVE stock is trading on the NASDAQ in the United States at $0.0002 in pre-market on 13 Mar 2026. The one-day change shows 19,900.00% and reported volume is 581 shares. Average volume sits at 1,883 shares, signaling very low liquidity and outsized percentage moves on small order flows. Market participants should treat the move as a liquidity-driven event, not broad investor conviction.

VIVE stock fundamentals and valuation

Viveve Medical, Inc. (VIVE) operates in Healthcare, Medical – Devices, and reports an EPS of -1.33. The company shows a market cap of $2,145.00 with 10,723,857 shares outstanding. Key ratios include a current ratio of 4.91, debt to equity 0.36, and revenue per share 0.6369. These figures show a company with working capital cushions but continued operating losses and negative free cash flow per share.

VIVE stock technicals, liquidity, and sector context

Technical indicators for VIVE stock show an RSI near 49.86, ADX 24.22, and a neutral momentum reading. On tiny volumes, standard technical signals are unreliable. The Medical – Devices sector shows steady demand for women’s health devices, but VIVE’s tiny market cap and thin trading separate its price action from sector peers. Traders should weigh sector tailwinds against company-level liquidity risk.

VIVE stock news, catalysts, and upcoming events

There is limited company-specific news tied to this pre-market spike. Investors should note the upcoming earnings release scheduled for 2026-03-20. For comparative context and peer data see the market comparison on Investing.com source. We also track VIVE on Meyka’s stock page for real-time updates Meyka VIVE page.

Meyka AI grade and technical analysis for VIVE stock

Meyka AI rates VIVE with a score out of 100: 65.09 | Grade: B | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Technicals show limited reliability given 581 shares traded today. This grade is informational only and not financial advice.

VIVE stock risks and opportunities

Primary risks include extremely low liquidity, micro market cap of $2,145.00, and sustained operating losses. Regulatory and adoption risks in women’s health device markets add uncertainty. Opportunities exist if commercial adoption of the Viveve System accelerates or if a strategic buyer emerges. Any material news before earnings could trigger volatile trading in VIVE stock.

Final Thoughts

VIVE stock’s pre-market spike to $0.0002 on 13 Mar 2026 is a liquidity-driven top-gainer event, not proof of broad market endorsement. Meyka AI’s forecast model projects a yearly price of $126.5983, which implies a theoretical upside of about 63,299,050% from today’s price. That projection is model-based and highly speculative. For practical planning, consider scenario targets: a conservative base-case target of $0.001 implies 400% upside, while a bullish target of $0.05 implies 24,900% upside. VIVE’s fundamentals show cash buffers per share and high operating losses, and its market cap at $2,145.00 limits institutional interest. Traders should prioritize liquidity, upcoming earnings on 2026-03-20, and any regulatory updates. Use Meyka AI as an AI-powered market analysis platform for real-time alerts, and treat all forecasts as model projections and not guarantees.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.